MicroRNAs in Medullary Thyroid Carcinoma: A State of the Art Review of the Regulatory Mechanisms and Future Perspectives

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2021 Apr 30

PMID 33924120

Citations 7

Authors

Francesca Galuppini

Simona Censi

Margherita Moro

Stefano Carraro

Marta Sbaraglia

Maurizio Iacobone

Matteo Fassan

Caterina Mian

Gianmaria Pennelli

Affiliations

Soon will be listed here.

Abstract

Medullary thyroid carcinoma (MTC) is a rare malignant neoplasia with a variable clinical course, with complete remission often difficult to achieve. Genetic alterations lead to fundamental changes not only in hereditary MTC but also in the sporadic form, with close correlations between mutational status and prognosis. In recent years, microRNAs (miRNAs) have become highly relevant as crucial players in MTC etiology. Current research has focused on their roles in disease carcinogenesis and development, but recent studies have expounded their potential as biomarkers and response predictors to novel biological drugs for advanced MTC. One such element which requires greater investigation is their mechanism of action and the molecular pathways involved in the regulation of gene expression. A more thorough understanding of these mechanisms will help realize the promising potential of miRNAs for MTC therapy and management.

Citing Articles

Holomics and Artificial Intelligence-Driven Precision Oncology for Medullary Thyroid Carcinoma: Addressing Challenges of a Rare and Aggressive Disease.

Luvhengo T, Moeng M, Sishuba N, Makgoka M, Jonas L, Mamathuntsha T Cancers (Basel). 2024; 16(20).

PMID: 39456563 PMC: 11505703. DOI: 10.3390/cancers16203469.

In Vitro Effects of Boric Acid on Cell Cycle, Apoptosis, and miRNAs in Medullary Thyroid Cancer Cells.

Yildirim O, Secme M, Dodurga Y, Mete G, Fenkci S Biol Trace Elem Res. 2024; 203(2):799-809.

PMID: 38689139 PMC: 11750916. DOI: 10.1007/s12011-024-04188-3.

Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.

Jung C, Agarwal S, Hang J, Lim D, Bychkov A, Mete O Endocr Pathol. 2023; 34(1):1-22.

PMID: 36890425 DOI: 10.1007/s12022-023-09753-5.

Modulatory role of miRNAs in thyroid and breast cancer progression and insights into their therapeutic manipulation.

Ahmed R, Samanta S, Banerjee J, Kar S, Dash S Curr Res Pharmacol Drug Discov. 2022; 3:100131.

PMID: 36568259 PMC: 9780070. DOI: 10.1016/j.crphar.2022.100131.

Update on the Diagnosis and Management of Medullary Thyroid Cancer: What Has Changed in Recent Years?.

Kaliszewski K, Ludwig M, Ludwig B, Mikula A, Greniuk M, Rudnicki J Cancers (Basel). 2022; 14(15).

PMID: 35892901 PMC: 9332800. DOI: 10.3390/cancers14153643.

References

Li J, Fu H, Xu C, Tie Y, Xing R, Zhu J . miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. BMC Cancer. 2010; 10:354. PMC: 2909210. DOI: 10.1186/1471-2407-10-354. View

Yu Y, Liu L, Ma R, Gong H, Xu P, Wang C . MicroRNA-127 is aberrantly downregulated and acted as a functional tumor suppressor in human pancreatic cancer. Tumour Biol. 2016; 37(10):14249-14257. DOI: 10.1007/s13277-016-5270-0. View

Lan S, Wu S, Zuchini R, Lin X, Su I, Tsai T . Autophagy-preferential degradation of MIR224 participates in hepatocellular carcinoma tumorigenesis. Autophagy. 2014; 10(9):1687-9. PMC: 4206546. DOI: 10.4161/auto.29959. View

Sun W, Lan X, Wang Z, Dong W, He L, Zhang T . MicroRNA-144 inhibits proliferation by targeting WW domain-containing transcription regulator protein 1 in papillary thyroid cancer. Oncol Lett. 2018; 15(1):1007-1013. PMC: 5772735. DOI: 10.3892/ol.2017.7440. View

Santarpia L, Calin G, Adam L, Ye L, Fusco A, Giunti S . A miRNA signature associated with human metastatic medullary thyroid carcinoma. Endocr Relat Cancer. 2013; 20(6):809-23. DOI: 10.1530/ERC-13-0357. View

Sharma S, Lin C, Farrugia M, McLaughlin S, Ellis E, Brundage K . MicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by suppressing the translation of RASA1 and SPRED1. Mol Cell Biol. 2014; 34(22):4143-64. PMC: 4248710. DOI: 10.1128/MCB.00480-14. View

Romeo P, Colombo C, Granata R, Calareso G, Gualeni A, Dugo M . Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients. Endocr Relat Cancer. 2018; 25(3):217-231. DOI: 10.1530/ERC-17-0389. View

Agirre X, Jimenez-Velasco A, Jose-Eneriz E, Garate L, Bandres E, Cordeu L . Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res. 2008; 6(12):1830-40. DOI: 10.1158/1541-7786.MCR-08-0167. View

Zhang W, Qian P, Zhang X, Zhang M, Wang H, Wu M . Autocrine/Paracrine Human Growth Hormone-stimulated MicroRNA 96-182-183 Cluster Promotes Epithelial-Mesenchymal Transition and Invasion in Breast Cancer. J Biol Chem. 2015; 290(22):13812-29. PMC: 4447958. DOI: 10.1074/jbc.M115.653261. View

10.

Packer A, Xing Y, Harper S, Jones L, Davidson B . The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease. J Neurosci. 2009; 28(53):14341-6. PMC: 3124002. DOI: 10.1523/JNEUROSCI.2390-08.2008. View

11.

Slabakova E, Culig Z, Remsik J, Soucek K . Alternative mechanisms of miR-34a regulation in cancer. Cell Death Dis. 2017; 8(10):e3100. PMC: 5682661. DOI: 10.1038/cddis.2017.495. View

12.

Zeng Y, Yi R, Cullen B . MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A. 2003; 100(17):9779-84. PMC: 187842. DOI: 10.1073/pnas.1630797100. View

13.

Xiang C, Cui S, Ke Y . MiR-144 inhibits cell proliferation of renal cell carcinoma by targeting MTOR. J Huazhong Univ Sci Technolog Med Sci. 2016; 36(2):186-192. DOI: 10.1007/s11596-016-1564-0. View

14.

Ogawa R, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Katada T . Expression profiling of micro-RNAs in human esophageal squamous cell carcinoma using RT-PCR. Med Mol Morphol. 2009; 42(2):102-9. DOI: 10.1007/s00795-009-0443-1. View

15.

Wang H, Zhu L, Yang Y, Wang Z, Wang R . MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G₁/S transition and apoptosis by targeting p21(WAF1/CIP1). Br J Cancer. 2014; 111(2):339-54. PMC: 4102932. DOI: 10.1038/bjc.2014.157. View

16.

Nass D, Rosenwald S, Meiri E, Gilad S, Tabibian-Keissar H, Schlosberg A . MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol. 2008; 19(3):375-83. PMC: 2728890. DOI: 10.1111/j.1750-3639.2008.00184.x. View

17.

Schwarzenbach H, Nishida N, Calin G, Pantel K . Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014; 11(3):145-56. DOI: 10.1038/nrclinonc.2014.5. View

18.

Moura M, Cavaco B, Pinto A, Domingues R, Santos J, Cid M . Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer. 2009; 100(11):1777-83. PMC: 2695700. DOI: 10.1038/sj.bjc.6605056. View

19.

Zhang A, Wang C, Lu H, Chen X, Ba Y, Zhang C . Altered Serum MicroRNA Profile May Serve as an Auxiliary Tool for Discriminating Aggressive Thyroid Carcinoma from Nonaggressive Thyroid Cancer and Benign Thyroid Nodules. Dis Markers. 2019; 2019:3717683. PMC: 6766139. DOI: 10.1155/2019/3717683. View

20.

Zhou J, Xie M, Shi Y, Luo B, Gong G, Li J . MicroRNA-153 functions as a tumor suppressor by targeting SET7 and ZEB2 in ovarian cancer cells. Oncol Rep. 2015; 34(1):111-20. DOI: 10.3892/or.2015.3952. View